1
|
Shi W, Tang J, Xiang J. Therapeutic strategies for aberrant splicing in cancer and genetic disorders. Clin Genet 2024; 105:345-354. [PMID: 38165092 DOI: 10.1111/cge.14478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2023] [Revised: 12/12/2023] [Accepted: 12/21/2023] [Indexed: 01/03/2024]
Abstract
Accurate pre-mRNA splicing is essential for proper protein translation; however, aberrant splicing is commonly observed in the context of cancer and genetic disorders. Notably, in genetic diseases, these splicing abnormalities often play a pivotal role. Substantial challenges persist in accurately identifying and classifying disease-induced aberrant splicing, as well as in development of targeted therapeutic strategies. In this review, we examine prevalent forms of aberrant splicing and explore potential therapeutic approaches aimed at addressing these splicing-related diseases. This summary contributes to a deeper understanding of the complexities about aberrant splicing and provide a foundation for the development of effective therapeutic interventions in the field of genetic disorders and cancer.
Collapse
Affiliation(s)
- Wenhua Shi
- Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, Hunan, China
- Hunan Key laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Jingqun Tang
- Hunan Key laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Department of Thoracic Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
| | - Juanjuan Xiang
- Cancer Research Institute, School of Basic Medical Science, Central South University, Changsha, Hunan, China
- Hunan Key laboratory of Early Diagnosis and Precise Treatment of Lung Cancer, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- NHC Key Laboratory of Carcinogenesis and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Xiangya Hospital, Central South University, Changsha, Hunan, China
| |
Collapse
|
2
|
Fujita J, Taniguchi M, Hashizume C, Ueda Y, Sakai S, Kondo T, Hashimoto-Nishimura M, Hanada K, Kosaka T, Okazaki T. Nuclear Ceramide Is Associated with Ataxia Telangiectasia Mutated Activation in the Neocarzinostatin-Induced Apoptosis of Lymphoblastoid Cells. Mol Pharmacol 2022; 101:322-333. [PMID: 35273080 DOI: 10.1124/molpharm.121.000379] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Accepted: 02/22/2022] [Indexed: 01/14/2023] Open
Abstract
Ceramide is a bioactive sphingolipid that mediates ionizing radiation- and chemotherapy-induced apoptosis. Neocarzinostatin (NCS) is a genotoxic anti-cancer drug that induces apoptosis in response to DNA double-strand breaks (DSBs) through ataxia telangiectasia mutated (ATM) activation. However, the involvement of ceramide in NCS-evoked nuclear events such as DSB-activated ATM has not been clarified. Here, we found that nuclear ceramide increased by NCS-mediated apoptosis through the enhanced assembly of ATM and the meiotic recombination 11/double-strand break repair/Nijmengen breakage syndrome 1 (MRN) complex proteins in human lymphoblastoid L-39 cells. NCS induced an increase of ceramide production through activation of neutral sphingomyelinase (nSMase) and suppression of sphingomyelin synthase (SMS) upstream of DSB-mediated ATM activation. In ATM-deficient lymphoblastoid AT-59 cells compared with L-39 cells, NCS treatment showed a decrease of apoptosis even though ceramide increase and DSBs were observed. Expression of wild-type ATM, but not the kinase-dead mutant ATM, in AT-59 cells increased NCS-induced apoptosis despite similar ceramide accumulation. Interestingly, NCS increased ceramide content in the nucleus through nSMase activation and SMS suppression and promoted colocalization of ceramide with phosphorylated ATM and foci of MRN complex. Inhibition of ceramide generation by the overexpression of SMS suppressed NCS-induced apoptosis through the inhibition of ATM activation and assembly of the MRN complex. In addition, inhibition of ceramide increased by the nSMase inhibitor GW4869 prevented NCS-mediated activation of the ATM. Therefore, our findings suggest the involvement of the nuclear ceramide with ATM activation in NCS-mediated apoptosis. SIGNIFICANCE STATEMENT: This study demonstrates that regulation of ceramide with neutral sphingomyelinase and sphingomyelin synthase in the nucleus in double-strand break-mimetic agent neocarzinostatin (NCS)-induced apoptosis. This study also showed that ceramide increase in the nucleus plays a role in NCS-induced apoptosis through activation of the ataxia telangiectasia mutated/meiotic recombination 11/double-strand break repair/Nijmengen breakage syndrome 1 complex in human lymphoblastoid cells.
Collapse
Affiliation(s)
- Jun Fujita
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Makoto Taniguchi
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Chieko Hashizume
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Yoshibumi Ueda
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Shota Sakai
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Tadakazu Kondo
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Mayumi Hashimoto-Nishimura
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Kentaro Hanada
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Takeo Kosaka
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| | - Toshiro Okazaki
- Division of General and Digestive Surgery, Department of Medicine (J.F., C.H., T.K.) and Medical Research Institute (M.T.), Kanazawa Medical University, Ishikawa, Japan; Research Institute for Bioresources and Biotechnology, Ishikawa Prefectural University, Ishikawa, Japan (C.H., T.O.); Graduate School of Arts and Sciences, The University of Tokyo, Tokyo, Japan (Y.U.); Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan. (S.S., K.H.); Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan (T.K.); and Department of Hematology/Oncology, Faculty of Medicine, Tottori University, Yonago, Japan (M.H.-N.)
| |
Collapse
|
3
|
Pitolli C, Marini A, Sette C, Pagliarini V. Non-Canonical Splicing and Its Implications in Brain Physiology and Cancer. Int J Mol Sci 2022; 23:ijms23052811. [PMID: 35269953 PMCID: PMC8911335 DOI: 10.3390/ijms23052811] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 02/28/2022] [Accepted: 03/02/2022] [Indexed: 02/01/2023] Open
Abstract
The advance of experimental and computational techniques has allowed us to highlight the existence of numerous different mechanisms of RNA maturation, which have been so far unknown. Besides canonical splicing, consisting of the removal of introns from pre-mRNA molecules, non-canonical splicing events may occur to further increase the regulatory and coding potential of the human genome. Among these, splicing of microexons, recursive splicing and biogenesis of circular and chimeric RNAs through back-splicing and trans-splicing processes, respectively, all contribute to expanding the repertoire of RNA transcripts with newly acquired regulatory functions. Interestingly, these non-canonical splicing events seem to occur more frequently in the central nervous system, affecting neuronal development and differentiation programs with important implications on brain physiology. Coherently, dysregulation of non-canonical RNA processing events is associated with brain disorders, including brain tumours. Herein, we summarize the current knowledge on molecular and regulatory mechanisms underlying canonical and non-canonical splicing events with particular emphasis on cis-acting elements and trans-acting factors that all together orchestrate splicing catalysis reactions and decisions. Lastly, we review the impact of non-canonical splicing on brain physiology and pathology and how unconventional splicing mechanisms may be targeted or exploited for novel therapeutic strategies in cancer.
Collapse
Affiliation(s)
- Consuelo Pitolli
- Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168 Rome, Italy; (C.P.); (C.S.)
- GSTEP-Organoids Research Core Facility, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy;
| | - Alberto Marini
- GSTEP-Organoids Research Core Facility, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy;
| | - Claudio Sette
- Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168 Rome, Italy; (C.P.); (C.S.)
- GSTEP-Organoids Research Core Facility, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy;
| | - Vittoria Pagliarini
- Department of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, 00168 Rome, Italy; (C.P.); (C.S.)
- GSTEP-Organoids Research Core Facility, IRCCS Fondazione Policlinico Universitario Agostino Gemelli, 00168 Rome, Italy;
- Correspondence:
| |
Collapse
|
4
|
Filippenkov IB, Stavchansky VV, Denisova AE, Valieva LV, Remizova JA, Mozgovoy IV, Zaytceva EI, Gubsky LV, Limborska SA, Dergunova LV. Genome-Wide RNA-Sequencing Reveals Massive Circular RNA Expression Changes of the Neurotransmission Genes in the Rat Brain after Ischemia-Reperfusion. Genes (Basel) 2021; 12:genes12121870. [PMID: 34946819 PMCID: PMC8701796 DOI: 10.3390/genes12121870] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 11/20/2021] [Accepted: 11/22/2021] [Indexed: 12/12/2022] Open
Abstract
Ischemic brain stroke is one of the most serious and socially significant diseases. In addition to messenger RNAs (mRNAs), encoding protein, the study of regulatory RNAs in ischemic has exceptional importance for the development of new strategies for neuroprotection. Circular RNAs (circRNAs) have a closed structure, predominantly brain-specific expression, and remain highly promising targets of research. They can interact with microRNAs (miRNAs), diminish their activity and thereby inhibit miRNA-mediated repression of mRNA. Genome-wide RNA-Seq analysis of the subcortical structures of the rat brain containing an ischemic damage focus and penumbra area revealed 395 circRNAs changed their expression significantly at 24 h after transient middle cerebral artery occlusion model (tMCAO) conditions. Furthermore, functional annotation revealed their association with neuroactive signaling pathways. It was found that about a third of the differentially expressed circRNAs (DECs) originate from genes whose mRNA levels also changed at 24 h after tMCAO. The other DECs originate from genes encoding non-regulated mRNAs under tMCAO conditions. In addition, bioinformatic analysis predicted a circRNA–miRNA–mRNA network which was associated with the neurotransmission signaling regulation. Our results show that such circRNAs can persist as potential miRNA sponges for the protection of mRNAs of neurotransmitter genes. The results expanded our views about the neurotransmission regulation in the rat brain after ischemia–reperfusion with circRNA action.
Collapse
Affiliation(s)
- Ivan B. Filippenkov
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
- Correspondence: ; Tel.: +7-499-196-1858
| | - Vasily V. Stavchansky
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
| | - Alina E. Denisova
- Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997 Moscow, Russia; (A.E.D.); (L.V.G.)
| | - Liya V. Valieva
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
| | - Julia A. Remizova
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
| | - Ivan V. Mozgovoy
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
| | - Elizaveta I. Zaytceva
- Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University, Leninskie Gory, 119991 Moscow, Russia;
| | - Leonid V. Gubsky
- Department of Neurology, Neurosurgery and Medical Genetics, Pirogov Russian National Research Medical University, Ostrovitianov str. 1, 117997 Moscow, Russia; (A.E.D.); (L.V.G.)
- Federal Center for the Brain and Neurotechnologies, Federal Biomedical Agency, Ostrovitianov str. 1, Building 10, 117997 Moscow, Russia
| | - Svetlana A. Limborska
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
| | - Lyudmila V. Dergunova
- Institute of Molecular Genetics of National Research Center “Kurchatov Institute”, Kurchatov Sq. 2, 123182 Moscow, Russia; (V.V.S.); (L.V.V.); (J.A.R.); (I.V.M.); (S.A.L.); (L.V.D.)
| |
Collapse
|
5
|
Wang Q, Wang T, Hu Y, Jiang W, Lu C, Zheng W, Zhang W, Chen Z, Cao H. Circ-EIF4G3 promotes the development of gastric cancer by sponging miR-335. Pathol Res Pract 2019; 215:152507. [PMID: 31257089 DOI: 10.1016/j.prp.2019.152507] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2019] [Revised: 05/27/2019] [Accepted: 06/20/2019] [Indexed: 01/23/2023]
Abstract
BACKGROUND Circular RNAs (circRNAs), a new group of endogenous non-coding RNAs, plays a crucial role in various types of carcinomas. However, there is still limited information on the involvement of circular RNAs in the setting of gastric cancer (GC). In the present study, we aimed to investigate circ-EIF4G3 status in clinical GC patient samples and explored the malignant biological behaviors. MATERIALS The expression of circ-EIF4G3 was determined by quantitative real time polymerase chain reaction (qRT-PCR). Microarray was performed to detect si-circ-EIF4G3 and unprocessed BGC-823 cells to find a cluster of differently expressed microRNAs (miRNAs) and bioinformatic tools including circinteractome, GO, NHGR1_GWAS, KEGG analyses were used in follow-up analysis. Luciferase reporter, RNA pull down and fluorescence in situ hybridization (FISH) assays were employed to explore the interaction between circ-EIF4G3 and miR-335. SiRNA-mediated knockdown of circ-EIF4G3, proliferation, migration and invasion in vitro were used to evaluate the function of circ-EIF4G3. RESULTS An increase level in the circ-EIF4G3 expression was associated with higher TNM stage and lymphatic metastasis. In vitro assays of the GC cell lines AGS and BGC-823 demonstrated that knockdown of circ-EIF4G3 inhibited cell proliferation, invasion and migration significantly. In addition, circ-EIF4G3 was identified as a sponge of miR-335, further promoting the proliferation, invasion and migration of GC cells. CONCLUSION Our study demonstrates that circ-EIF4G3 promotes the proliferation, invasion and migration of gastric cancer via sponging miR-335.
Collapse
Affiliation(s)
- Qian Wang
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Tiegang Wang
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China; Department of General Surgery, Nanjing Red Cross Hospital, Nanjing, China
| | - Yun Hu
- Department of General Surgery, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Wei Jiang
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Chen Lu
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Wubin Zheng
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
| | - Wenling Zhang
- Department of Gastroenterology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
| | - Ziyi Chen
- Department of General Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu, China.
| | - Hongyong Cao
- Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
| |
Collapse
|
6
|
Fernández-García P, Rosselló CA, Rodríguez-Lorca R, Beteta-Göbel R, Fernández-Díaz J, Lladó V, Busquets X, Escribá PV. The Opposing Contribution of SMS1 and SMS2 to Glioma Progression and Their Value in the Therapeutic Response to 2OHOA. Cancers (Basel) 2019; 11:cancers11010088. [PMID: 30646599 PMCID: PMC6356341 DOI: 10.3390/cancers11010088] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 12/31/2018] [Accepted: 01/08/2019] [Indexed: 12/13/2022] Open
Abstract
Background: 2-Hydroxyoleic acid (2OHOA) is particularly active against glioblastoma multiforme (GBM) and successfully finished a phase I/IIA trial in patients with glioma and other advanced solid tumors. However, its mechanism of action is not fully known. Methods: The relationship between SMS1 and SMS2 expressions (mRNA) and overall survival in 329 glioma patients was investigated, and so was the correlation between SMS expression and 2OHOA's efficacy. The opposing role of SMS isoforms in 2OHOA's mechanism of action and in GBM cell growth, differentiation and death, was studied overexpressing or silencing them in human GBM cells. Results: Patients with high-SMS1 plus low-SMS2 expression had a 5-year survival ~10-fold higher than patients with low-SMS1 plus high-SMS2 expression. SMS1 and SMS2 also had opposing effect on GBM cell survival and 2OHOA's IC50 correlated with basal SMS1 levels and treatment induced changes in SMS1/SMS2 ratio. SMSs expression disparately affected 2OHOA's cancer cell proliferation, differentiation, ER-stress and autophagy. Conclusions: SMS1 and SMS2 showed opposite associations with glioma patient survival, glioma cell growth and response to 2OHOA treatment. SMSs signature could constitute a valuable prognostic biomarker, with high SMS1 and low SMS2 being a better disease prognosis. Additionally, low basal SMS1 mRNA levels predict positive response to 2OHOA.
Collapse
Affiliation(s)
- Paula Fernández-García
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
- Lipopharma Therapeutics, Isaac Newton, 07121 Palma de Mallorca, Spain.
| | - Catalina A Rosselló
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
- Lipopharma Therapeutics, Isaac Newton, 07121 Palma de Mallorca, Spain.
| | - Raquel Rodríguez-Lorca
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - Roberto Beteta-Göbel
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
- Lipopharma Therapeutics, Isaac Newton, 07121 Palma de Mallorca, Spain.
| | - Javier Fernández-Díaz
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
- Lipopharma Therapeutics, Isaac Newton, 07121 Palma de Mallorca, Spain.
| | - Victoria Lladó
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - Xavier Busquets
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
| | - Pablo V Escribá
- Laboratory of Molecular Cell Biomedicine, University of the Balearic Islands, 07122 Palma de Mallorca, Spain.
| |
Collapse
|